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Exosomes, first isolated 30 years ago, are nanoscale vesicles shed by most types of cells. The nucleic acid
rich content of these nanoparticles, floating in virtually all bodily fluids, has great potential for non-invasive
molecular diagnostics and may represent a novel therapeutic delivery system. However, current isolation
techniques such as ultracentrifugation are not convenient and do not result in high purity isolation. This
represents an interesting challenge for microfluidic technologies, from a cost-effective perspective as well
as for enhanced purity capabilities, and point-of-care acquisition and diagnosis. In this frontier review, we
present the current challenges, comment the first microfluidic advances in this new field and propose a
roadmap for future developments. This review enables biologists and clinicians familiar with exosome
enrichment to assess the performance of novel microfluidic devices and, equally, enables microfluidic
engineers to educate themselves about this new class of promising biomarker-rich particles and the chal-
lenges arising from their clinical use.1 Introduction
Extracellular vesicles (EVs) are membrane-bound structures
that are released by most, if not all, cell types. Due to their
“cargo” of protein, RNA and DNA from their cell of origin,
EVs offer a minimally-invasive ‘window’ into the intra-cellular
world.1,2 In the literature, differing nomenclature and classifi-
cation of EVs has been used based on size, density, morphol-
ogy, lipid composition, protein composition, and subcellular
origin.3 Exosomes are distinguished from other EV subtypes
by their unique intra-cellular biogenesis, in contrast with
other EVs, such as microparticles, that are shed directly from
the cell membrane.3 Exosomes are reported to measure 20–
100 nm and appear cup-shaped when visualized by transmis-
sion electron microscopy. Exosomes are first formed as intra-
luminal vesicles by budding into early endosomes and multi-
vesicular bodies (MVBs). Subsequently, the MVBs either fuse
with lysosomes or with the plasma membrane and the endo-
somes are released into the extra-cellular milieu to become
exosomes.4 Due to this specific formation process, exosomes
contain a cargo that, to some extent, mirrors the cell of
origin.
The observation that the proteome and transcriptome of
exosomes changes according to the cell of origin5,6 and theability to access exosomes from virtually any biological
fluid (including saliva, lymph, urine, milk, blood, synovial
and amniotic fluids7) forms the rationale for the use of
exosomes as non-invasive biomarkers for disease and
toxicity.8–10
Exosomes can also behave as inter-cellular signals by
transferring functional mRNA and microRNA between cells
in vitro.2,11 The importance of exosomal signalling in vivo
remains to be determined. This signalling capacity may
enable exosomes to be used as a non-immunogenic RNA
delivery system that can cross natural divisions such as the
blood–brain barrier.12,132. Conventional exosome capturing
Current methods for exosome ‘capturing’ concentrate exo-
somes, but do not isolate them. Contamination of exosome
preparations with non-exosomal proteins and other EV sub-
types can lead to spurious biomarker discovery studies and
incorrect conclusions about exosome biological activity.14
The isolation of a pure population of exosomes would facili-
tate studies in exosome biology, in particular regarding their
physiological functions and their roles in various pathologies.
While next-generation deep sequencing (NGS) provides
fast profiling of miRNA or other biomarkers in biological
fluids, including from exosomes, liquid biopsy sample prep-
aration is sometimes crucial to reliably differentiate between
diseased and healthy patients.15,16 In this case, the isolation
of exosomes can improve the sensitivity of biomarker ampli-
fication and reduce the number of false-negative results.16
The most common method used for concentrating exosomesoyal Society of Chemistry 2015



















































































View Article Onlineis ultracentrifugation, a method that includes differential
centrifugation steps reaching speeds of up to 200 000 × g.
However, this procedure is time consuming (4–5 hours),17
requires specialist laboratory equipment that is not available
in routine hospital laboratories, and is inefficient with
regard to exosome yield (5–25% recovery).18 Variations on
this method, such as adding in a sucrose gradient centrifu-
gation step, lead to higher purity of extracted exosomes.
However, the more complicated the sample processing the
longer the time from sample to exosome preparation. The
capital cost of an ultracentrifuge is typically around $50–
100k and the running cost is around $3k per year. Addition-
ally it requires training and a dedicated team. Exosomes can
be isolated in as little as two hours but isolation time ranges
from 2 to 10 hours depending on the biofluid and protocol.
It may be difficult for standard hospital laboratories and
resource-poor countries to acquire and maintain such equip-
ment, thus denying exosome-based diagnostics to a substan-
tial part of the population. A promising method for EV
selective concentration relies on antibody-coated magnetic
beads. This technique results in higher recovery and purity –
at least two-fold more exosome markers and proteins mea-
sured in the exosome concentrate compared to ultracentrifu-
gation.19 The use of magnetic beads also facilitates the use
of standard analysis methods, such as flow cytometry,
immuno-blot and electron microscopy on exosome-bead
complexes.20 However, it is important to highlight that the
magnetic beads only attach to exosomes that contain the
targeted protein that might not be present in all the exo-
somes in the sample resulting in a biased analysis. Recently,
commercial precipitation kits like ExoQuick™ and Total
Exosome Isolation™ precipitation solution have become
available. The advantages of these kits are that they are easy
to use with only 1 or 2 steps and do not require any expen-
sive equipment or advanced technical know-how. The disad-
vantage is that they commonly require a lengthy overnight
incubation step and their mode-of-action has not been
disclosed. The purity of the acquired exosomes has been
reported to be inferior compared to OptiPrep density gradi-
ent centrifugation, as demonstrated by lower enrichment of
exosomal marker proteins and more contaminating proteins
such as extra-cellular argonaute 2 complexes.21 Chemicals
originating from the precipitation kit may contaminate the
prep and these commonly undisclosed chemicals may affect
the apparent biological activity of the exosomes. Micro-
filtration techniques and other size exclusion methods can
suffer from clogging and vesicle trapping issues and often
entail shear stress-induced damages. This paper focuses on
the potential of microfluidic devices to concentrate, and
even isolate, exosomes, describing the most recent techno-
logical developments and highlighting pro and cons of each
of these methods that promise to deliver rapid and easy iso-
lation. In this review we have chosen to focus on the diag-
nostics rather therapeutic use of exosomes, as microfluidic
solutions will be most beneficial, or at least of immediate
benefit, in the diagnostic area.This journal is © The Royal Society of Chemistry 20153. Microfluidic technologies for
exosome isolation
The advent of microfluidic technologies has allowed the
development of new exosome manipulation techniques
which, though still at an early stage of development (most of
these were developed between 2012 and 2015), are proving
themselves extremely convenient in terms of reagent vol-
umes, product purity and isolation time (cf. ESI† Table for
detailed comparison of techniques). The techniques devel-
oped so far for microfluidic-based exosomal purification can
be classified in three categories including (i) trapping exo-
somes with an immune-affinity approach, (ii) sieving (e.g.
nanoporous membranes) or (iii) trapping exosomes on
porous structures (e.g. nanowire-on-micropillars). Sieving
approach differs from the others by the possibility to start
from whole blood without previous treatment. However, all
methods require further off-chip additional steps for sample
preparation, such as plasma extraction, or reagent mixing.223.1 Immunological separation
Immuno-chip. Chen et al. demonstrated the first immune
affinity approach for the capture of exosomes within a micro-
fluidic device.23 The separation principle relies on receptors
on the exosome outer surface which enable specific collection
according to their origin and function, and allow their isola-
tion from other shed membrane particles and lipid struc-
tures. The device features a planar structure with herring-
bone engravings to enhance mixing (cf. Fig. 1a). Collected
exosomes are characterised in situ, after several washing
steps, or lysed for DNA extraction.23 Chen et al. demonstrated
a faster method (~1 h), with respect to the traditional tech-
nologies, that used smaller amounts of reagents (100–400 μl).
Total RNA amount, extracted from exosomes captured on-
chip using CD63 antibodies (common exosomal marker)
from 400 μL serum samples, was around 30 ng for non-small
cell lung cancer patients. Further analyses demonstrated the
quality and quantity of on-chip exosomal RNA was sufficient
for the evaluation of tumor-derived RNA.
Immuno-chips and on-chip fluorescent characterisation.
Kanwar et al.22 used the same principle, modifying the prior
design so as to carry out “on chip” exosome quantification by
a fluorescent assay method on a standard read-out plate
reader. The device, called Exochip, features several circular
wells connected by narrow channels, in order to enhance
mixing (Fig. 1b–d). Additionally, the extended retention time
leads to a stronger interaction between the exosomes and the
functionalised surface. Besides being specially adapted for
further analysis, the device can also be easily scaled up, sim-
ply adding more rows of wells in the same chip. The protein
yield of the ExoChip exosomes was 15–18 μg of total protein
and 10–15 ng of total nucleic acid from 400 μL serum sam-
ples. A higher level of fluorescence on the chip was measured
in exosomes obtained from patients with pancreatic cancer
compared to healthy volunteers. This was in line with theLab Chip, 2015, 15, 2388–2394 | 2389
Fig. 1 (a) The first chip realised for microfluidic exosome isolation
featured a 19 mm × 20 μm × 4.5 cm chamber with herringbone groves
10 μm deep to enhance contact between microparticles and chip
surface. The device is pictured here is filled with supernatant fluid and
attached to a syringe pump. Reproduced from ref. 23 with the
permission of the Royal Society of Chemistry. (b) A modified version of
the same scheme: single channel Exochip, the device has the same
dimensions of a standard glass-side (W = 0.75 mm, L = 73 mm, P = 9
mm, H = 100 μm). Up to 12 channels could fit within the dimensions of
a microtiter-plate. (c) Experimental setup using a 3 channels Exochip (d)
Exochip working scheme: exosomes counting is made possible through
a simple 3 steps procedure involving: (i) blood serum infusion within the
chip (pre-coated with exosome-specific capture antibodies, anti-CD63),
(ii) staining with specifically functionalised (Di-O) fluorescent dye, (iii)
on chip analysis through conventional counting methods. Reproduced
from ref. 22 with the permission of the Royal Society of Chemistry.



















































































View Article Onlinerelatively higher protein expression of CD63 and Rab5 mea-
sured in the exosomes from the cancer patients (western
blot). A panel of miRNAs measured in the extracted exosomes
was also able to distinguish between cancer patients and
healthy volunteers. He et al.24 developed a cascading chip
where exosome isolation and enrichment, chemical lysis, pro-
tein immuno-precipitation and sandwich immunoassay
assisted by chemi-fluorescence detection are integrated in a
microfluidic circuit. The on-chip isolation protocol takes less
than 1.5 hours and only requires 30 μl of human plasma
premixed with antibody-labelled magnetic beads. The analy-
sis of type 1 insulin growth factor receptor (IGF-1R) concen-
tration in on-chip exosomes, though 100 times lower than
that recovered from ultracentrifugation, showed a clear
overexpression of the marker in 5 non-small-cell lung cancer
patients compared to 6 healthy volunteers confirming the
diagnostic potential of this approach. As mentioned in
section 2, one of the main limitations of immunological anal-
ysis is its focus on only one particular surface protein at a
time.
Immuno-chips and sensing. Several groups are proposing
to use immunological techniques in combination with differ-
ent techniques, allowing for better separation, or detection,
or both. In this regard, Im et al.25 devised an on-chip nano2390 | Lab Chip, 2015, 15, 2388–2394plasmonic exosome sensor (nPLEX), in which surface
plasmon resonance (SPR, a technique based on the oscilla-
tions of electrons at an interface stimulated by incident light)
is used through nanohole arrays patterned on a metal film.
Each array is functionalised with different affinity ligands
specific for a particular surface protein, which overcomes the
issue highlighted in the previous section. In the first chip
generation each of 12 microfluidic channels were coupled
with 3 arrays (12 × 3), giving the possibility to monitor and
display bonds with 36 different proteins. A second generation
of chips is being developed, implementing 33 × 33 arrays
thus allowing increased data collection from 1089 sites.
Thanks to the high sensitivity of the plasmonic sensors, it is
possible to display in real time the intensity of exosome-site
bonds, and “map” the activity of each array, thus leading to a
quantitative analysis of exosome content. Exosomes were
present in large quantities (>109 exosomes per mL) in ascitic
fluid from 20 ovarian cancer patients and 10 non-cancer
patients. Therefore the nPLEX device could function with
samples simply collected through a 0.2 μm membrane filter.
Receiver operator characteristic curve analysis of exosomes
using paired protein levels per exosome of epithelial cell
adhesion markers (EpCAM) and CD24 resulted in a promis-
ing area under the curve of 0.97. This device performs well
with exosome-rich ascites samples, but due to its sensitivity
and high-throughput has potential as a point-of-care diagnos-
tic tool on more conventional liquid biopsies such as blood,
if combined with an integrated sample preparation. Further-
more, its use could be broadened to diagnose a range of ill-
nesses or even to monitor treatment response. Another exam-
ple of enhanced on-chip immunological separation followed
by detection was proposed by Vaydianathan et al. with an
original approach named “nanoshearing” aimed at reducing
non-specific fouling as well as providing inline detection.26
The use of this electrodynamic anti-fouling technique led to
a 3-fold enrichment in detection sensitivity relatively to a nor-
mal hydrodynamic flow.
Immuno-binding and inertial solution exchange. Finally,
Dudani et al.,27 used an off-chip immunological approach to
bind exosomes to 20 μm polystyrene beads followed by on-
chip inertial focusing to enrich the bead-exosome complex
from the original sample into a buffer. The device was tested
with blood samples (after RBC lysis) spiked with centrifuged
melanoma and breast cancer culture supernatant. This
mixture was incubated for 4 h with polystyrene beads
functionalised with exosome-specific antibodies and then
processed through the chip. There, inertial lift forces push
the beads toward the centre of a channel with multiple out-
lets, transferring them into a wash buffer and allowing their
selective separation. A single centrifugation step removed the
larger cell debris and the exosomes can then be eluted from
the beads and characterized. The device features a relatively
high throughput (70 μl min−1, five-fold higher than most
other microfluidic techniques) and demonstrated the enrich-
ment of exosomes but still needs a thorough molecular char-
acterisation of the retrieved material. The 4 h needed forThis journal is © The Royal Society of Chemistry 2015
Fig. 3 Ciliated structures for exosome isolation and capture by Wang
et al. The hierarchical geometry of the device does not allow cells
larger than 1 μm to access the wired area, due to the distance
between the pillars (b) being too narrow (900 nm). Smaller cell debris
can enter the micropillar area but are excluded by the ciliated nano
structure (a), which forms pores with diameters ranging between 30
and 200 nm, in order to selectively trap exosomes and small EVs.
Smaller proteins and molecules are free to pass through the device
without being captured. Reproduced from ref. 7 with the permission of
the Royal Society of Chemistry.



















































































View Article Onlinebead incubation makes it unsuitable for acute care
applications.
In conclusion, it is important to highlight that immuno-
logical methodologies are the only ones, so far developed,
which can be directed towards the isolation of a pure exo-
some population. Other methods relying on physical proper-
ties (size, density, surface charge) lead to higher percentages
of contaminants (similar micro-particles with different origin,
proteins).
3.2 Sieving
Davies et al.28 developed a different approach to exosome col-
lection, by sieving EVs directly from whole blood through a
membrane and driving filtration either by pressure or electro-
phoresis (cf. Fig. 2). The pressure-driven solution leads to a
shorter separation time while the electric field produces a
higher purity of the extracted vesicles, proteins being less
affected by electric fields than phospholipidic vesicles, due to
their lower negative charge.29 In the authors' opinion, the
non-selectivity of this device with respect to vesicle type can
be seen as an advantage compared to the over-specific collec-
tion offered by immune-affinity related methods, which can
lead to biased data analysis. A significant drawback is the
low exosome recovery (unspecified in the text but shown to
be next to 2% in a graph) while the device seems to perform
well regarding separation time. The device reached a satura-
tion point after 3–4 μL of filtrate was extracted when pressure
driven filtration was used. However this volume was enough
to assess the exosomal cargo by western blot and RT-PCR.
When electro-driven filtration was used, the average yield was
79 ng RNA per 100 μg of protein from a 100 μL sample, com-
pared to 187 ng of RNA per 100 μg of proteins from a 5 mL
sample obtained by centrifugation.
3.3. Trapping on porous structures
Wang et al.7 devised a third approach consisting of trapping
EVs through a porous microstructure. They designed aThis journal is © The Royal Society of Chemistry 2015
Fig. 2 Schematics for two sieving modes for exosome filtration. The
membrane is realised by in situ photopatterning of a porous polymer
monolith. Sieving can be performed by (a) applying pressure on an
on-chip dead end filter or (b) by applying an electric field to drive the
exosomes through the porous membrane in a hybrid solution of cross
flow and electrophoresis sorting. Vesicles damage through the device
was shown to be undetectable by analysing haemolysis and DNA was
not contaminated by intracellular proteins. Adapted from ref. 28 with
the permission of the Royal Society of Chemistry.ciliated micropillar structure forming a microporous silicon
nano-wire which was able to selectively trap particles in
the range of 40–100 nm (Fig. 3). According to Wang et al.
this method allows the selective collection of intact
phospholipidic “exosome-like” vesicles. Though the trapping
step is relatively fast (~10 min), to proceed with imaging and
characterisation, it is necessary to dissolve the silicon nano-
wire in PBS buffer overnight, thus making the recovery proce-
dure time consuming. This device was tested with a solution
containing 83 nm and 120 nm lipid vesicles and 500 nm
nanoparticles. The highest retention (60%) was obtained for
83 nm vesicles when up to 30 μL of sample was injected
(based on fluorescent intensity measured with a plate reader,
starting concentration undisclosed), followed by 120 nm vesi-
cles (45%), while the retention of 500 nm bead was only
10%. The retention rate of 83 and 120 nm lipid vesicles
decreased when more sample volume was injected, probably
due to a saturation effect. The device was not validated with
clinical samples, and no analysis of cargo protein or RNA was
performed.4. Road map for microfluidic
exosomal isolation
The increased interest in the role of exosomes in biomarker
discovery and diagnostics has highlighted the pressing need
for new technologies to isolate exosomes in biofluids rapidly
and accurately with minimal sample preparation. Here we
discuss 5 areas of consideration for future developments.Lab Chip, 2015, 15, 2388–2394 | 2391



















































































View Article Online4.1. From research to clinical setting: increased speed and
lower cost
Ultracentrifugation is currently used in the research setting,
but not yet regularly used in the clinical setting. If an
exosome-based diagnostic was to be used in real-life clinical
medicine, one could envisage that in a non-urgent situation,
such as the diagnosis of cancer, the use of a centralised labo-
ratory with an ultracentrifugation unit could be feasible, pro-
viding the extraction is reproducible. However if standardised
performance is demonstrated using microfluidic chips, it
would open the door for faster, reliable, cost-effective exo-
some-based diagnostics for emergencies in acute care set-
tings (e.g., myocardial infections and drug toxicity) as well as
non-emergency illnesses (cancer diagnostics). Furthermore,
this could allow a more accurate exosomes analysis, since
studies have indicated that there is a significant loss in exo-
somes number from biofluids such as urine, even when
frozen at −80 °C30 and within 2 h.31 If exosomes are to be
used for acute care, the device would ideally allow the biolo-
gist or clinician to rapidly and confidently isolate exosomes
from biofluids within a 30 minute time frame after sample
collection.4.2. Future directions, technological considerations and
potential challenges for the development of microfluidic
technologies
All prototypes presented in this review have used a single
isolation strategy and none are free from issues. Future
microfluidic devices might therefore benefit from hybrid
approaches using two or more isolation techniques, for
example, a first separation based on size could eliminate the
largest blood cells from a blood samples, followed by an
immunological separation to access a specific exosome pop-
ulation. The challenge, as with all microfluidic development,
is to provide a solution to a real clinical question. Two
routes are likely to emerge: the first will explore the exo-
some biology in the research area, and will require refined
isolation. For this route, the advantage of microfluidics will
be to provide cheaper alternative to ultracentrifugation with
low capital investment. The second route will focus on the
development of tools to facilitate liquid biopsy preparation
for next generation sequencing. The challenge will lie in the
rapid extraction from complex matrices. To fit in a clinical
work flow the devices will need to be more robust and cost-
effective as their current counterparts. The challenges in the
development will lie in (i) reducing the cost of the devices,
a consideration which will need to be taken into account at
the design stage, and which might involve alleviating the
need for structures below 80 μm, at which point photoli-
thography might be replaceable by rapid-prototyping and
high volume manufacturing processes. (ii) Secondly,
achieving the right throughput will be crucial and might
necessitate stacking several microfluidic units on the same
device.2392 | Lab Chip, 2015, 15, 2388–23944.3. Achieving specificity and reproducibility
As discussed above, in some cases, devices will need to reli-
ably provide an exosome preparation specific to an organ of
origin. If a device has on-chip technologies such as protein
specific markers for sorting exosomes from specific organs it
allows the clinician access to a relevant exosome population
specifically to his site of interest. Current methods of isola-
tion are not delivering on reproducibility of exosome recov-
ery, arguably due to variations in sample handling. Ideally,
microfluidic chips should be tested by different laboratories
to assess reproducibility and consistency and demonstrate
standardised performance.
4.5. Characterisation and biological validation
At present, the methods of quantifying exact or ideal exo-
somal yield are still very semi-quantitative. There is an unmet
need for quantitative and qualitative assessment of exosomes
and the definition of clear biological controls.32 We have
demonstrated that nanoparticle tracking analysis is a promis-
ing method for quantifying exosomes in biofluids, such as
urine31 and it would therefore be interesting to compare the
yield of current and future devices using this method. How-
ever, there is no “one fits all” solution for the characterisa-
tion of exosomes. The characterisation required will depend
on the clinical application. Spiking-in labelled exosomes
offers a reliable method to determine the yield, either via
fluorescence measuring or RT-PCR. Furthermore, it is
recommended to assess not only the presence of the selected
markers (yield) but also the absence of contaminants
(specificity).32
5. Conclusion
Through highly precise fluid control and high surface to vol-
ume ratios, microfluidics has the power to differentiate, cap-
ture, enrich and isolate particles of very similar sizes and
shapes. Despite being in its infancy, several microfluidic
developments have demonstrated effective exosome separa-
tion, leading to robust clinical diagnostics. However none of
the first prototypes are free from issues, in particular they
often require prior sample preparation based on macro-scale
procedures. Among the aforementioned methods, immuno-
logical separation leads to high specificity, and can be
performed in a fairly short time in most cases (~1.5 h). Trap-
ping exosomes in porous structure, such as ciliated micro-pil-
lars, seemingly leads to high purity exosomes recovery, but
the recovery procedure is currently time consuming (over 1
day). Sieving is a particularly interesting method as it can be
performed directly on whole blood, without any treatment
before the separation, but it is not exempt from drawbacks,
such as low recovery and the possibility of damage to vesicles
due to shear stress. Some isolation techniques demonstrated
for microvesicles (typically of diameter above 100 nm) might
also be suitable for exosome recovery.33,34 For example, Rho
et al. have demonstrated a rapid and sensitive microvesicleThis journal is © The Royal Society of Chemistry 2015



















































































View Article Onlinedetection in packed red blood cell units using filter-assisted
filtration, magnetic labelling and target-specific detection via
miniaturised nuclear magnetic resonance system.33 Detection
and characterisation are an essential part of the capture-to-
diagnosis path, and some microfluidic researchers have
focused all, or part, of their efforts towards the development
of detection techniques which could be the subject of
another focused review.25,35–37 Some of these techniques pro-
pose the direct (preparation free) detection of exosomal RNA
from raw cell medium, which could be potentially applicable
to bodily fluids.37 The applications of microfluidic technology
to bodily fluids for exosome isolation have not been
described extensively with few devices using clinical samples,
and microfluidic engineers should seek to establish strong
collaboration with biologists and clinicians to demonstrate
the full potential of the technology. While current ultracentri-
fugation techniques require significant capital and mainte-
nance costs, microfluidic-based exosome isolation techniques
are promising and cost-effective, and could be deployed in a
large number of clinics and hospitals, as well as in resource-
scarce settings.
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